2004_CD SkyePharma_NNP Annual_JJ Report_NNP 75_CD Reconciliation_NNP to_TO US_NNP Accounting_NNP Principles_NNPS Reconciliation_NNP to_TO Accounting_NNP Principles_NNPS The_DT financial_JJ statements_NNS of_IN the_DT Group_NNP are_VBP prepared_VBN in_IN accordance_NN with_IN generally_RB accepted_VBN accounting_NN principles_NNS in_IN the_DT UK_NNP UK_NNP GAAP_NNP which_WDT differs_VBZ in_IN certain_JJ respects_NNS from_IN those_DT applicable_JJ in_IN the_DT US_NNP US_NNP GAAP_NNP ._.
The_DT tables_NNS below_IN summarise_NN the_DT material_NN adjustments_NNS to_TO the_DT loss_NN and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP for_IN the_DT applicable_JJ years_NNS ._.
Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD restated_VBN Notes_NNS 000_CD 000_CD Loss_NN under_IN UK_NNP GAAP_NNP 24,296_CD 43,223_CD US_NNP GAAP_NNP adjustments_NNS :_: Purchase_NN accounting_NN and_CC goodwill_NN Amortisation_NNP of_IN goodwill_NN and_CC other_JJ intangibles_NNS 1_CD 3,744_CD 3,664_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS 1_CD 985_CD 823_CD Deferred_JJ taxes_NNS 1_CD 54_CD 139_CD Share-based_JJ compensation_NN 4_CD 1,006_CD 751_CD Revenue_NN recognition_NN 5_CD 13,052_CD 13,386_CD Sale_NNP of_IN royalty_NN interests_NNS Revenue_NN recognition_NN 6_CD 1,237_CD 6,126_CD Interest_NN expense_NN 6_CD 8,694_CD 9,609_CD Royalty_NN payments_NNS expensed_VBD 6_CD 2,977_CD 3,144_CD Financial_NNP instruments_NNS 7_CD 516_CD 146_CD Investments_NNPS 8_CD 1,893_CD Share_NN of_IN loss_NN in_IN associate_JJ 9_CD 3,809_CD 1,554_CD Expenses_NNS of_IN convertible_JJ bond_NN exchange_NN 10_CD 1,913_CD Net_JJ loss_NN under_IN US_NNP GAAP_NNP 20,767_CD 38,638_CD Net_JJ loss_NN per_IN Ordinary_NNP Share_NNP under_IN US_NNP GAAP_NNP pence_NN 3.4_CD p_NN 6.3_CD p_NN 31_CD December_NNP 2003_CD 31_CD December_NNP 2004_CD restated_VBN Notes_NNS 000_CD 000_CD Shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 63,623_CD 84,870_CD US_NNP GAAP_NNP adjustments_NNS :_: Purchase_NN accounting_NN and_CC goodwill_NN Goodwill_NNP 1_CD 89,362_CD 85,226_CD Other_JJ intangible_JJ fixed_JJ assets_NNS 1_CD 3,997_CD 4,378_CD Tangible_JJ fixed_JJ assets_NNS 1_CD 6,974_CD 7,946_CD Deferred_JJ taxes_NNS 1_CD 1,632_CD 1,578_CD Contingent_JJ consideration_NN charged_VBN to_TO goodwill_NN reserve_NN 1_CD 22,620_CD 22,620_CD Shares_NNS issued_VBN relating_VBG to_TO contingent_JJ consideration_NN 2_CD 11,310_CD 11,310_CD Shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN ,_, deferred_VBN shares_NNS and_CC shares_NNS issued_VBN 3_CD 11,310_CD 11,310_CD Share-based_JJ compensation_NN 4_CD 1,461_CD Deferred_JJ revenue_NN 5_CD 411_CD 10,887_CD Funding_NNP liabilities_NNS 6_CD 50,363_CD 51,224_CD Financial_NNP instruments_NNS 7_CD 162_CD 354_CD Fixed_VBN asset_NN investments_NNS 8_CD 543_CD Fixed_VBN asset_NN investments_NNS Investments_NNP in_IN associates_NNS 9_CD 11,107_CD 7,298_CD Convertible_JJ debt_NN 10_CD 1,913_CD Shareholders_NNS funds_NNS under_IN US_NNP GAAP_NNP 84,699_CD 94,434_CD 76_CD SkyePharma_NNP Annual_JJ Report_NNP 2004_CD Reconciliation_NNP to_TO US_NNP Accounting_NNP Principles_NNPS continued_VBD Revised_VBN accounting_NN for_IN ESOTs_NNS and_CC employee_NN share_NN schemes_NNS in_IN 2004_CD 3_CD Deferred_JJ shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN Under_IN UK_NNP GAAP_NNP ,_, contingent_JJ Under_IN UK_NNP GAAP_NNP ,_, the_DT Group_NNP adopted_VBD UITF_NNP Abstract_NNP 38_CD :_: Accounting_NNP for_IN ESOP_NNP consideration_NN on_IN the_DT acquisition_NN of_IN Jago_NNP has_VBZ been_VBN estimated_VBN and_CC trusts_NNS for_IN the_DT 2004_CD financial_JJ statements_NNS as_IN explained_VBN in_IN note_NN 1_CD :_: Accounting_NNP recognized_VBD within_IN shareholders_NNS funds_NNS as_IN deferred_JJ shares_NNS ._.
As_IN a_DT result_NN ,_, shares_NNS in_IN SkyePharma_NNP PLC_NNP held_VBN by_IN the_DT Groups_NNS employee_NN were_VBD recorded_VBN using_VBG the_DT market_NN price_NN at_IN the_DT date_NN of_IN issuance_NN of_IN deferred_JJ share_NN ownership_NN trusts_NNS ESOTs_NNS have_VBP been_VBN reclassified_VBN from_IN fixed_VBN asset_NN shares_NNS ._.
Under_IN US_NNP GAAP_NNP contingent_JJ consideration_NN has_VBZ not_RB been_VBN recognized_VBN ._.
investments_NNS and_CC are_VBP now_RB treated_VBN as_IN a_DT deduction_NN from_IN shareholders_NNS funds_NNS until_IN such_JJ time_NN as_IN the_DT shares_NNS in_IN the_DT trust_NN vest_NN unconditionally_RB in_IN employees_NNS ._.
In_IN 4_CD Share-based_JJ compensation_NN Under_IN UK_NNP GAAP_NNP no_DT expense_NN for_IN share_NN addition_NN ,_, revisions_NNS to_TO UITF_NNP Abstract_NNP 17_CD :_: Employee_NN share_NN schemes_NNS have_VBP changed_VBN options_NNS has_VBZ been_VBN recognized_VBN as_IN the_DT exercise_NN price_NN equals_VBZ the_DT market_NN the_DT basis_NN on_IN which_WDT the_DT costs_NNS of_IN employee_NN share_NN schemes_NNS are_VBP charged_VBN to_TO the_DT price_NN at_IN the_DT date_NN of_IN grant_NN ._.
Under_IN UK_NNP GAAP_NNP the_DT prior_JJ year_NN comparatives_NNS have_VBP been_VBN restated_VBN for_IN the_DT adoption_NN of_IN UITF_NNP 38_CD ,_, the_DT revisions_NNS to_TO UITF_NNP I7_NNP were_VBD not_RB material_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP applies_VBZ APB_NNP 25_CD and_CC a_DT compensation_NN expense_NN has_VBZ been_VBN recognized_VBN for_IN performance-based_JJ compensation_NN plans_NNS Under_IN US_NNP GAAP_NNP ,_, own_JJ shares_NNS held_VBN are_VBP shown_VBN as_IN a_DT deduction_NN from_IN variable_JJ plans_NNS where_WRB it_PRP is_VBZ probable_JJ that_IN the_DT performance_NN criteria_NNS will_MD be_VB shareholders_NNS funds_NNS ._.
The_DT change_NN in_IN UK_NNP GAAP_NNP as_IN described_VBN above_IN eliminates_VBZ met_VBN and_CC the_DT options_NNS exercised_VBN prior_RB to_TO the_DT expiration_NN of_IN the_DT options_NNS issued_VBD the_DT material_NN GAAP_NNP difference_NN in_IN the_DT way_NN that_IN the_DT ESOT_NNP is_VBZ accounted_VBN for_IN under_IN these_DT plans_NNS ._.
No_DT compensation_NN expense_NN has_VBZ been_VBN recognized_VBN for_IN between_IN UK_NNP and_CC US_NNP GAAP_NNP ._.
The_DT summary_NN of_IN adjustments_NNS between_IN UK_NNP and_CC those_DT plans_NNS that_WDT are_VBP considered_VBN fixed_VBN options_NNS plans_NNS and_CC where_WRB the_DT options_NNS US_NNP GAAP_NNP has_VBZ been_VBN restated_VBN to_TO reflect_VB the_DT restated_VBN UK_NNP GAAP_NNP figures_NNS ._.
granted_VBN under_IN the_DT plans_NNS are_VBP granted_VBN at_IN a_DT price_NN that_WDT equals_VBZ the_DT market_NN price_NN at_IN the_DT date_NN of_IN grant_NN ._.
1_CD Business_NN combinations_NNS Under_IN both_DT UK_NNP and_CC US_NNP GAAP_NNP acquisitions_NNS of_IN subsidiary_NN undertakings_NNS have_VBP been_VBN accounted_VBN for_IN as_IN acquisitions_NNS and_CC the_DT 5_CD Revenue_NN recognition_NN Under_IN UK_NNP GAAP_NNP revenue_NN is_VBZ recognized_VBN when_WRB it_PRP purchase_VB consideration_NN has_VBZ been_VBN allocated_VBN to_TO the_DT net_JJ assets_NNS acquired_VBN at_IN is_VBZ earned_VBN and_CC non-refundable_JJ and_CC to_TO the_DT extent_NN that_IN there_EX are_VBP no_DT future_JJ their_PRP$ fair_JJ value_NN at_IN the_DT date_NN of_IN acquisition_NN ,_, with_IN the_DT difference_NN treated_VBN as_IN obligations_NNS pursuant_JJ to_TO the_DT revenue_NN ,_, in_IN accordance_NN with_IN the_DT contract_NN goodwill_NN ._.
In_IN the_DT allocation_NN of_IN consideration_NN ,_, and_CC the_DT treatment_NN of_IN deferred_VBN terms_NNS ._.
Refundable_JJ revenue_NN is_VBZ treated_VBN as_IN deferred_VBN until_IN such_PDT a_DT time_NN as_IN consideration_NN ,_, certain_JJ differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP arise_VB as_RB set_VBN it_PRP is_VBZ no_RB longer_RBR refundable_JJ ._.
Under_IN US_NNP GAAP_NNP ,_, SAB_NNP 104_CD requires_VBZ deferral_JJ out_IN below_IN ._.
and_CC amortisation_NN of_IN up-front_JJ licensing_NN fees_NNS where_WRB there_EX is_VBZ a_DT continuing_VBG involvement_NN with_IN the_DT licensed_JJ asset_NN through_IN the_DT provision_NN of_IN research_NN Under_IN UK_NNP GAAP_NNP ,_, prior_RB to_TO the_DT introduction_NN of_IN FRS10_NNP ,_, goodwill_NN was_VBD written_VBN and_CC development_NN services_NNS ,_, manufacturing_VBG services_NNS or_CC other_JJ similar_JJ off_IN to_TO reserves_NNS and_CC has_VBZ not_RB been_VBN reinstated_VBN on_IN the_DT balance_NN sheet_NN ._.
activities_NNS even_RB if_IN the_DT fee_NN is_VBZ non-refundable_JJ ._.
As_IN a_DT result_NN ,_, under_IN US_NNP GAAP_NNP certain_JJ non-refundable_JJ up-front_JJ payments_NNS have_VBP been_VBN deferred_VBN over_IN US_NNP GAAP_NNP requires_VBZ an_DT allocation_NN of_IN the_DT purchase_NN consideration_NN to_TO the_DT development_NN period_NN of_IN the_DT contract_NN term_NN on_IN certain_JJ agreements_NNS ._.
identifiable_JJ intangible_JJ assets_NNS ,_, including_VBG any_DT resulting_VBG from_IN acquired_VBN in-process_JJ research_NN and_CC development_NN ._.
Prior_RB to_TO 2002_CD ,_, goodwill_NN was_VBD Deferred_JJ revenue_NN reflects_VBZ the_DT amount_NN of_IN revenue_NN not_RB currently_RB eligible_JJ amortised_VBN over_IN its_PRP$ useful_JJ life_NN ._.
Since_IN 1_CD January_NNP 2002_CD goodwill_NN is_VBZ no_RB longer_RBR for_IN recognition_NN under_IN US_NNP GAAP_NNP as_RB well_RB as_IN the_DT reversal_NN of_IN deferred_JJ income_NN amortised_VBN under_IN US_NNP GAAP_NNP ,_, but_CC instead_RB subject_JJ to_TO annual_JJ impairment_NN under_IN UK_NNP GAAP_NNP related_VBN to_TO the_DT sale_NN of_IN royalty_NN interests_NNS ,_, since_IN this_DT is_VBZ tests_NNS ._.
This_DT results_NNS in_IN a_DT reversal_NN of_IN goodwill_NN amortisation_NN charged_VBN under_IN recorded_VBN as_IN funding_NN liabilities_NNS under_IN US_NNP GAAP_NNP ._.
Intangible_JJ fixed_JJ assets_NNS recognized_VBN under_IN US_NNP GAAP_NNP purchase_NN accounting_NN requirements_NNS are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN revenue_NN 6_CD Sale_NNP of_IN royalty_NN interests_NNS Under_IN UK_NNP GAAP_NNP payments_NNS received_VBD from_IN a_DT earning_VBG life_NN ._.
Negative_JJ goodwill_NN ,_, if_IN any_DT ,_, is_VBZ eliminated_VBN by_IN reducing_VBG the_DT third_JJ party_NN in_IN return_NN for_IN the_DT sale_NN of_IN a_DT proportion_NN of_IN potential_JJ future_JJ royalty_NN value_NN of_IN all_DT non-current_JJ assets_NNS acquired_VBN ._.
streams_NNS from_IN a_DT selection_NN of_IN products_NNS ,_, and_CC used_VBD to_TO fund_VB the_DT internal_JJ research_NN and_CC development_NN of_IN products_NNS ,_, are_VBP reflected_VBN within_IN other_JJ The_NNP Group_NNP effected_VBD the_DT acquisition_NN of_IN Jago_NNP and_CC Krypton_NNP through_IN the_DT operating_NN income_NN when_WRB the_DT risk_NN of_IN reimbursement_NN has_VBZ effectively_RB been_VBN exchange_NN of_IN warrants_NNS and_CC shares_NNS ._.
The_DT issuance_NN of_IN certain_JJ shares_NNS is_VBZ transferred_VBN to_TO the_DT third_JJ party_NN ._.
Royalties_NNS paid_VBD to_TO third_JJ parties_NNS are_VBP treated_VBN contingent_JJ upon_IN the_DT occurrence_NN of_IN certain_JJ future_JJ events_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, as_IN cost_NN of_IN goods_NNS sold_VBN ._.
the_DT fair_JJ value_NN of_IN the_DT contingent_JJ consideration_NN has_VBZ been_VBN estimated_VBN to_TO determine_VB the_DT acquisition_NN cost_NN and_CC the_DT resulting_VBG goodwill_NN has_VBZ been_VBN US_NNP GAAP_NNP requires_VBZ such_JJ payments_NNS to_TO be_VB recorded_VBN as_IN debt_NN where_WRB there_EX eliminated_VBN against_IN shareholders_NNS funds_NNS ._.
is_VBZ continuing_VBG involvement_NN in_IN the_DT generation_NN of_IN the_DT cash_NN flows_VBZ due_JJ to_TO the_DT third_JJ party_NN ._.
The_DT US_NNP GAAP_NNP adjustment_NN for_IN the_DT statement_NN of_IN operations_NNS Under_IN US_NNP GAAP_NNP contingent_JJ consideration_NN is_VBZ recognized_VBN only_RB when_WRB the_DT includes_VBZ the_DT reversal_NN of_IN other_JJ UK_NNP GAAP_NNP operating_VBG income_NN recorded_VBN contingency_NN is_VBZ resolved_VBN and_CC consideration_NN is_VBZ issued_VBN or_CC becomes_VBZ issuable_JJ ._.
from_IN the_DT third_JJ party_NN offset_VBN by_IN recording_VBG the_DT interest_NN charge_NN for_IN the_DT period_NN on_IN the_DT outstanding_JJ US_NNP GAAP_NNP debt_NN balance_NN ._.
Repayments_NNS made_VBD to_TO third_JJ Under_IN US_NNP GAAP_NNP deferred_VBD taxation_NN associated_VBN with_IN certain_JJ purchase_NN parties_NNS in_IN the_DT form_NN of_IN royalty_NN payments_NNS that_WDT are_VBP expensed_VBN under_IN UK_NNP GAAP_NNP accounting_NN differences_NNS has_VBZ also_RB been_VBN recorded_VBN ._.
are_VBP reversed_VBN under_IN US_NNP GAAP_NNP and_CC are_VBP treated_VBN as_IN repayment_NN of_IN debt_NN ._.
2_CD Shares_NNS issued_VBN related_VBN to_TO contingent_JJ consideration_NN In_IN April_NNP 2002_CD the_DT In_NNP order_NN to_TO record_VB this_DT funding_NN liability_NN in_IN accordance_NN with_IN US_NNP GAAP_NNP ,_, Deferred_NNP A_NNP Shares_NNP were_VBD automatically_RB converted_VBN into_IN Ordinary_NNP Shares_NNP on_IN royalty_NN cash_NN flows_NNS are_VBP periodically_RB reassessed_VBN and_CC recorded_VBN within_IN the_DT the_DT first_JJ commercial_JJ launch_NN of_IN Paxil_NNP CR_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT shares_NNS operating_VBG subsidiary_NN that_IN ultimately_RB received_VBN the_DT funds_NNS ._.
Under_IN FAS_NNP 52_CD :_: were_VBD recorded_VBN at_IN the_DT market_NN price_NN at_IN the_DT date_NN of_IN conversion_NN ._.
Foreign_JJ currency_NN translation_NN ,_, movements_NNS in_IN currency_NN rates_NNS related_VBN to_TO monetary_JJ liabilities_NNS are_VBP expensed_VBN to_TO the_DT profit_NN and_CC loss_NN and_CC translation_NN differences_NNS upon_IN consolidation_NN are_VBP recorded_VBN in_IN equity_NN ._.
2004_CD SkyePharma_NNP Annual_JJ Report_NNP 77_CD 7_CD Financial_NNP instruments_NNS Under_IN UK_NNP GAAP_NNP ,_, periodic_JJ gains_NNS and_CC loses_VBZ on_IN US_NNP GAAP_NNP developments_NNS interest_NN and_CC foreign_JJ currency_NN derivatives_NNS are_VBP not_RB recognized_VBN until_IN the_DT In_NNP December_NNP 2004_CD ,_, the_DT FASB_NNP issued_VBD Statement_NNP of_IN Financial_NNP Accounting_NNP operational_JJ transactions_NNS to_TO which_WDT they_PRP are_VBP linked_VBN occur_VBP ._.
Under_IN US_NNP GAAP_NNP ,_, Standards_NNP No._NN ._.
123R_CD SFAS_NNP 123R_NNP :_: Share-Based_NNP Payment_NN which_WDT revises_VBZ SFAS_NNP the_DT Group_NNP records_NNS all_DT derivative_JJ instruments_NNS on_IN the_DT balance_NN sheet_NN at_IN fair_JJ 123_CD and_CC supersedes_VBZ APB_NNP 25_CD ._.
SFAS_NNP 123R_NNP requires_VBZ that_IN the_DT cost_NN of_IN all_DT sharevalue_NN with_IN changes_NNS in_IN fair_JJ values_NNS recorded_VBN in_IN earnings_NNS ._.
In_IN addition_NN ,_, if_IN based_VBN payment_NN transactions_NNS be_VB recognized_VBN in_IN the_DT financial_JJ statements_NNS ._.
SFAS_NNP embedded_VBD derivatives_NNS are_VBP identified_VBN ,_, they_PRP are_VBP recorded_VBN separately_RB from_IN 123R_NNP also_RB establishes_VBZ fair_JJ value_NN as_IN the_DT measurement_NN method_NN in_IN accounting_VBG their_PRP$ host_NN contracts_NNS at_IN fair_JJ value_NN ,_, with_IN changes_NNS in_IN fair_JJ value_NN recognized_VBN in_IN for_IN share-based_JJ payments_NNS to_TO employees_NNS ._.
FAS_NNP 123R_NNP is_VBZ to_TO be_VB applied_VBN in_IN reporting_VBG current_JJ earnings_NNS ._.
The_DT Group_NNP is_VBZ assessing_VBG the_DT impact_NN of_IN adoption_NN of_IN this_DT standard_NN ._.
8_CD Fixed_VBN asset_NN investments_NNS Under_IN UK_NNP GAAP_NNP fixed_JJ asset_NN investments_NNS are_VBP stated_VBN at_IN the_DT lower_JJR of_IN cost_NN and_CC net_JJ realisable_JJ value_NN ._.
In_IN September_NNP 2004_CD ,_, the_DT Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP reached_VBD a_DT consensus_NN on_IN EITF_NNP Issue_NNP No._NN ._.
02-14_CD :_: Whether_IN an_DT Investor_NN Should_MD Apply_VB the_DT Under_IN US_NNP GAAP_NNP ,_, securities_NNS which_WDT are_VBP determined_VBN to_TO be_VB available-for-sale_JJ Equity_NN Method_NN of_IN Accounting_NN to_TO Investments_NNP Other_JJ Than_IN Common_NNP Stock_NNP ,_, are_VBP stated_VBN at_IN fair_JJ value_NN and_CC any_DT unrealised_JJ gains_NNS or_CC losses_NNS are_VBP included_VBN as_IN in_IN which_WDT the_DT Task_NNP Force_NNP reached_VBD the_DT consensus_NN that_IN an_DT investor_NN that_WDT has_VBZ the_DT a_DT separate_JJ component_NN of_IN shareholders_NNS funds_NNS ._.
ability_NN to_TO exercise_VB significant_JJ influence_NN over_IN the_DT operating_NN and_CC financial_JJ policies_NNS of_IN the_DT investee_NN should_MD apply_VB the_DT equity_NN method_NN of_IN accounting_NN when_WRB it_PRP has_VBZ an_DT 9_CD Fixed_VBN asset_NN investments_NNS Investments_NNP in_IN associates_NNS Under_IN UK_NNP GAAP_NNP investment_NN in_IN common_JJ stock_NN and_CC or_CC an_DT investment_NN that_WDT is_VBZ in-substance_JJ the_DT company_NN has_VBZ accounted_VBN for_IN its_PRP$ investment_NN in_IN Astralis_NNP as_IN an_DT associated_VBN common_JJ stock_NN ._.
The_DT consensus_NN of_IN this_DT EITF_NNP is_VBZ to_TO be_VB applied_VBN in_IN reporting_NN periods_NNS undertaking_VBG from_IN December_NNP 2004_CD ,_, when_WRB it_PRP gained_VBD significant_JJ influence_NN ,_, beginning_VBG after_IN 15_CD September_NNP 2004_CD ._.
We_PRP do_VBP not_RB believe_VB the_DT adoption_NN of_IN this_DT as_IN described_VBN in_IN note_NN 12_CD :_: Fixed_VBN Asset_NNP Investments_NNP ._.
standard_NN will_MD have_VB a_DT material_NN impact_NN on_IN our_PRP$ financial_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT ability_NN to_TO exercise_VB significant_JJ influence_NN results_NNS in_IN a_DT change_NN in_IN classification_NN from_IN an_DT available_JJ for_IN sale_NN investment_NN to_TO an_DT In_IN March_NNP 2004_CD ,_, the_DT EITF_NNP reached_VBD a_DT consensus_NN on_IN EITF_NNP Issue_NNP No._NN ._.
03-1_CD :_: The_DT equity_NN method_NN investment_NN under_IN APB_NNP 18_CD :_: Equity_NNP method_NN of_IN accounting_NN for_IN Meaning_NNP of_IN Other-Than-Temporary_NNP Impairment_NNP and_CC Its_PRP$ Application_NN to_TO Certain_NNP investments_NNS in_IN common_JJ stock_NN ._.
On_IN initial_JJ application_NN of_IN the_DT equity_NN method_NN ,_, Investments_NNP EITF_NNP 03-1_CD ._.
The_DT guidance_NN prescribed_VBN a_DT three-step_JJ model_NN for_IN under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP must_MD retroactively_RB restate_VB the_DT investment_NN ,_, determining_VBG whether_IN an_DT investment_NN is_VBZ impaired_VBN and_CC results_NNS of_IN operations_NNS and_CC retained_VBN earnings_NNS in_IN a_DT manner_NN consistent_JJ with_IN requires_VBZ disclosure_NN for_IN unrealised_JJ losses_NNS on_IN investments_NNS ._.
In_IN September_NNP 2004_CD ,_, the_DT accounting_NN for_IN a_DT step_NN acquisition_NN of_IN a_DT subsidiary_NN which_WDT is_VBZ different_JJ the_DT FASB_NNP issued_VBD FASB_NNP Staff_NNP Position_NNP EITF_NNP 03-1-1_CD :_: Effective_NNP Date_NNP of_IN Paragraphs_NNPS to_TO the_DT treatment_NN under_IN UK_NNP GAAP_NNP ._.
This_DT constitutes_VBZ a_DT change_NN in_IN accounting_NN 10-20_CD of_IN EITF_NNP Issue_NNP No._NN ._.
FSP_NNP EITF_NNP 03-1-1_CD delays_NNS the_DT principle_NN ._.
In_IN consideration_NN of_IN this_DT change_NN in_IN status_NN ,_, the_DT investment_NN in_IN effective_JJ date_NN for_IN the_DT measurement_NN and_CC recognition_NN guidance_NN contained_VBN in_IN Astralis_NNP has_VBZ been_VBN adjusted_VBN for_IN increases_NNS in_IN ownership_NN interest_NN according_VBG paragraphs_NNS 10-20_CD of_IN EITF_NNP 03-1_CD ._.
The_DT disclosure_NN requirements_NNS of_IN EITF_NNP 03-1_CD to_TO the_DT accounting_NN for_IN a_DT step_NN acquisition_NN and_CC reduced_VBN to_TO recognize_VB the_DT remain_VBP effective_JJ for_IN fiscal_JJ years_NNS ending_VBG after_IN 15_CD June_NNP 2004_CD ._.
No_DT effective_JJ date_NN Groups_NNS share_NN of_IN the_DT losses_NNS of_IN Astralis_NNP after_IN the_DT date_NN of_IN initial_JJ acquisition_NN ._.
for_IN the_DT measurement_NN and_CC recognition_NN guidance_NN has_VBZ been_VBN established_VBN in_IN This_DT change_NN in_IN accounting_NN principle_NN results_NNS in_IN a_DT decrease_NN to_TO the_DT carrying_VBG FSP_NNP EITF_NNP 03-1-1_CD ._.
During_IN the_DT period_NN of_IN delay_NN ,_, FSP_NNP EITF_NNP 03-1-1_CD states_NNS that_IN value_NN of_IN Astralis_NNP by_IN 6.9_CD million_CD at_IN 31_CD December_NNP 2003_CD and_CC an_DT increase_NN companies_NNS should_MD continue_VB to_TO apply_VB current_JJ guidance_NN to_TO determine_VB if_IN an_DT in_IN the_DT losses_NNS recorded_VBD as_IN a_DT result_NN of_IN the_DT equity_NN method_NN of_IN 1.6_CD million_CD impairment_NN is_VBZ other-than-temporary_JJ ._.
The_DT adoption_NN of_IN EITF_NNP 03-1_CD ,_, excluding_VBG for_IN the_DT year_NN ended_VBD 2003_CD ._.
paragraphs_NNS 10-20_CD ,_, did_VBD not_RB impact_VB the_DT Groups_NNS consolidated_JJ position_NN ,_, results_NNS of_IN operations_NNS or_CC cash_NN flows_NNS ._.
The_DT Group_NNP will_MD assess_VB the_DT impact_NN of_IN paragraphs_NNS 10_CD Convertible_JJ debt_NN Under_IN UK_NNP GAAP_NNP the_DT Group_NNP exchanged_VBD 49.6_CD million_CD 10-20_CD of_IN EITF_NNP 03-1_CD once_IN the_DT guidance_NN has_VBZ been_VBN finalized_VBN ._.
of_IN its_PRP$ convertible_JJ debt_NN due_JJ 2005_CD for_IN convertible_JJ debt_NN in_IN the_DT same_JJ amount_NN due_JJ 2024_CD ._.
The_DT Group_NNP wrote-off_NN the_DT issue_NN costs_VBZ associated_VBN with_IN the_DT original_JJ convertible_JJ debt_NN due_JJ 2005_CD as_IN an_DT exceptional_JJ item_NN in_IN 2004_CD ._.
Under_IN US_NNP GAAP_NNP the_DT exchange_NN is_VBZ treated_VBN as_IN a_DT modification_NN according_VBG to_TO EITF_NNP 96-19_CD and_CC therefore_RB costs_NNS associated_VBN with_IN the_DT exchange_NN of_IN debt_NN of_IN 49.6_CD million_CD due_JJ 2024_CD have_VBP been_VBN expensed_VBN ._.
Company_NN Information_NN and_CC Advisors_NNP Registered_NNP and_CC Head_NNP Office_NNP Bankers_NNP 105_CD Piccadilly_NNP National_NNP Westminster_NNP Bank_NNP plc_NN London_NNP W1J_NNP 7NJ_NNP Bishopsgate_NNP Business_NNP Centre_NNP Telephone_NNP :_: 020 7491 1777_CD PO_NNP Box_NNP 34_CD Fax_NNP :_: 020 7491 3338_CD 15_CD Bishopsgate_NNP Registered_NNP No_NNP :_: 107582_CD London_NNP EC2P_NNP 2AP_NNP Secretary_NNP :_: Douglas_NNP Parkhill_NNP Registrars_NNPS Auditors_NNS Capita_NNP Registrars_NNPS LLP_NNP The_DT Registry_NNP Chartered_NNP Accountants_NNPS 34_CD Beckenham_NNP Road_NNP 1_CD Embankment_NNP Place_NNP Beckenham_NNP London_NNP WC2N_NNP 6RH_NNP Kent_NNP BR3_NNP 4TU_NNP Solicitors_NNPS Depositary_NNP UK_NNP The_NNP Bank_NNP of_IN New_NNP York_NNP Stringer_NNP Saul_NNP 101_CD Barclay_NNP Street_NNP 17_CD Hanover_NNP Square_NNP New_NNP York_NNP London_NNP W1S_NNP 1HU_NNP NY_NNP 10286_CD USA_NNP US_NNP Sullivan_NNP &_CC Cromwell_NNP 1_CD New_NNP Fetter_NNP Lane_NNP London_NNP EC4A_NNP 1AN_NNP Corporate_NNP Broker_NNP and_CC Financial_NNP Adviser_NNP Credit_NNP Suisse_NNP First_NNP Boston_NNP 20_CD Columbus_NNP Courtyard_NNP London_NNP E14_NNP 4DA_NNP
